|
POU5F1P3
|
Yolk Sac Tumor
|
0.030 |
GeneticVariation |
BEFREE |
A bilateral primary yolk sac tumor of the lung associated with chromosome 3 polysomy: understanding the Oct 3/4 and Sox 2 interaction.
|
23114647 |
2013 |
|
POU5F1P3
|
Yolk Sac Tumor
|
0.030 |
Biomarker |
BEFREE |
GDF3 positivity, in the absence of OCT3/4 and CD30, combined with morphological features, is helpful in the diagnosis of yolk sac tumor.
|
19396148 |
2009 |
|
POU5F1P3
|
Yolk Sac Tumor
|
0.030 |
AlteredExpression |
BEFREE |
OCT4 marked the nuclei of 6 cases, among which 5 cases also showed glypican 3 expression indicative of an admixed yolk sac tumor component.
|
20096442 |
2010 |
|
POU5F1P3
|
Uveal melanoma
|
0.010 |
AlteredExpression |
BEFREE |
Presence of undifferentiated cells in the UM was demonstrated by the expression of stem cell markers ATP-binding cassette sub-family G member 2 (ABCG2) and octamer-binding protein 4 (OCT4).
|
22815634 |
2012 |
|
POU5F1P3
|
Uterine Fibroids
|
0.010 |
Biomarker |
BEFREE |
Based on the results of present study and published reports showing the presence of pluripotent markers (OCT-4, NANOG and SOX2) in human myometrial side population and expression of particularly OCT-4A in human leiomyomas, we speculate that these nuclear OCT-4 positive stem cells located in the perimetrium are the possible tumor initiating cells leading to the development of leiomyomas rather than the mesenchymal cells which express cytoplasmic OCT-4B.
|
28438190 |
2017 |
|
POU5F1P3
|
Urothelial Carcinoma
|
0.010 |
AlteredExpression |
BEFREE |
Among them, nuclear paraspeckle assembly transcript 1 (NEAT1), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) and urothelial carcinoma-associated 1 (UCA1) were validated as Oct4 transcriptional targets through promoter or enhancer activation.
|
28615056 |
2017 |
|
POU5F1P3
|
Turner Syndrome
|
0.010 |
AlteredExpression |
BEFREE |
OCT4 gonadal gene expression related to the presence of Y-chromosome sequences in Turner syndrome.
|
20347080 |
2010 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
Biomarker |
BEFREE |
Oct4 and Nanog are reported to promote tumor progression in several cancers, but the effect on intrahepatic cholangiocarcinoma (ICC) is unknown.
|
30854141 |
2019 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
AlteredExpression |
BEFREE |
Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells.
|
18676852 |
2008 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
Biomarker |
BEFREE |
Currently, some studies have shown that OCT4 has a dual function in suppressing or promoting cancer progression.
|
31012189 |
2019 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
Biomarker |
BEFREE |
The correlation of OCT4, but not CD133, with the invasiveness of bladder cancer revealed that OCT4 can be considered as a key regulator of tumor progression, aggressive behavior, and metastasis; therefore, OCT4 can be a potential marker for targeted therapy of bladder cancer.
|
26945449 |
2017 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
Biomarker |
BEFREE |
More importantly, downregulation of β-catenin could effectively prevent its enrichment in nuclei and then significantly downregulate the expression of proteins, such as vimentin, Snail, MMP-2, MMP-9, CD44, Nanog, and Oct4 to prevent tumor progression and metastasis.
|
30540162 |
2019 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
AlteredExpression |
BEFREE |
However, the mechanism by which Oct4 directs transcriptional program that leads to somatic cancer progression remains unclear.
|
25609695 |
2015 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
AlteredExpression |
BEFREE |
Circulating tumor cells (CTCs) with epithelial-to-mesenchymal transition (EMT) phenotypes might be related to tumor progression while OCT4 expression is involved in tumor metastasis and poor prognosis.
|
28374320 |
2017 |
|
POU5F1P3
|
Tumor Progression
|
0.080 |
Biomarker |
BEFREE |
Oct4-mediated tumor cell dedifferentiation may have an important role during tumor progression.
|
22286766 |
2012 |
|
POU5F1P3
|
Tumor Initiation
|
0.030 |
Biomarker |
BEFREE |
NANOG-GFP+ cells gave rise to both GFP+ and GFP(-) cells, and GFP+ cells possessed increased levels of the embryonic stem cell transcription factors NANOG, SOX2, and OCT4 and elevated self-renewal and tumor initiation capacities.
|
25827713 |
2015 |
|
POU5F1P3
|
Tumor Initiation
|
0.030 |
AlteredExpression |
BEFREE |
As cancer stem cells (CSCs) are required for tumor initiation and growth, we investigated expression of OCT4 and NANOG in the setting of decreased MAOA expression.
|
29844571 |
2018 |
|
POU5F1P3
|
Tumor Initiation
|
0.030 |
AlteredExpression |
BEFREE |
The ZnAs@SiO<sub>2</sub> NPs also inhibited tumor spheroid formation <i>in vitro</i> and tumor initiation <i>in vivo</i> and induced significant changes in the expression of stemness markers (CD133, Sox-2, and Oct-4) and EMT markers (E-cadherin, Vimentin, and Slug) both <i>in vitro</i> and <i>in vivo.</i> These effects of ZnAs@SiO<sub>2</sub> that correlated with prognosis of HCC were mediated by the SHP-1/JAK2/STAT3 signaling.
|
31285768 |
2019 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
Biomarker |
BEFREE |
The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line.
|
28454439 |
2017 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
Biomarker |
BEFREE |
The underlying mechanisms may involve the regulation of stem cell markers (CD133, Nestin, OCT4 and Nanog) to reduce the self-renewal ability and regulate the NF-κB1 signaling pathway and inhibit U251s glioma stem-like cell invasion.
|
30509101 |
2019 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
Biomarker |
BEFREE |
Hypoxia also enhanced the expression of cancer stem cell (CSC) transcription factors (NANOG, Oct4, SOX2), CD133 and EMT markers (N-cadherin, Vimentin), thereby supporting invasion.
|
31634481 |
2019 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
GeneticVariation |
BEFREE |
This process involves the decreased expression of the stemness-related genes Oct-4 and Nanog and the invasion-related gene MMP-9.
|
23043761 |
2013 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
Biomarker |
BEFREE |
The results demonstrated that Oct4 enhanced cell invasion and adhesion accompanied by the downregulation of epithelial marker cytokeratin, and upregulation of the mesenchymal markers vimentin and N‑cadherin.
|
25420671 |
2015 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
Biomarker |
BEFREE |
Loss-of-functional indicated that, in BCSC cells (MDA-MB-231 CSC, MCF-7 CSC), FEZF1-AS1 knockdown reduced the CD44<sup>+</sup> /CD24<sup>-</sup> rate, the mammosphere-forming ability, stem factors (Nanog, Oct4, SOX2), and inhibited the proliferation, migration and invasion.
|
29797562 |
2018 |
|
POU5F1P3
|
Tumor Cell Invasion
|
0.100 |
Biomarker |
BEFREE |
Due to existence of transcriptional linkage between DPPA2/Nanog and OCT4 in mouse ESCs, our results suggest that a pluripotency transcriptional network consisting of SALL4/OCT4/DPPA2/Nanog, as similar as ESCs, is activated in CRC which not only play essential roles in maintenance of stemness state and self-renewal characteristics of tumor cells, but also in progression of CRC cells through advanced stages leading to increase depth of tumor cell invasion.
|
25497006 |
2015 |